Patents by Inventor Michel C. Vellard

Michel C. Vellard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Variants of C-type Natriuretic Peptide
    Publication number: 20120316114
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Application
    Filed: May 8, 2012
    Publication date: December 13, 2012
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
  • MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN LYSOSOMAL SULFATASE ENZYMES AND USES THEREOF
    Publication number: 20120208221
    Abstract: This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.
    Type: Application
    Filed: February 10, 2012
    Publication date: August 16, 2012
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Michel C. Vellard, Vish Koppaka, Melita Dvorak-Ewell, Erno Pungor, Charles Hague
  • MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN N-ACETYLGALACTOSAMINE-6-SULFATASE AND USES THEREOF
    Publication number: 20120189605
    Abstract: This invention provides compositions of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase (GALNS), and pharmaceutical compositions and formulations thereof, methods of producing and purifying GALNS, and its use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the GALNS enzyme, e.g., Mucopolysaccharidosis IVa (MPS IVa or Morquio A syndrome).
    Type: Application
    Filed: July 22, 2011
    Publication date: July 26, 2012
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vish Koppaka, Michel C. Vellard, Augustus O. Okhamafe, Kidisti Araya
  • Variants of C-type natriuretic peptide
    Patent number: 8198242
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: June 12, 2012
    Assignee: Biomarin Pharmaceutical Inc.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
  • Variants of C-Type Natriuretic Peptide
    Publication number: 20100297021
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Application
    Filed: May 20, 2010
    Publication date: November 25, 2010
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
  • METHODS OF ENHANCING YIELD OF ACTIVE IGA PROTEASE
    Publication number: 20100261252
    Abstract: The present disclosure relates in general to methods for recombinantly producing soluble, active IgA proteases (e.g., IgA1 proteases) in host cells (e.g., bacterial cells), and methods for using IgA proteases (e.g., IgA1 proteases) produced by the methods to treat IgA deposition disorders (e.g., IgA nephropathy).
    Type: Application
    Filed: April 9, 2010
    Publication date: October 14, 2010
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Shinong Long, Michel C. Vellard
  • Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof
    Publication number: 20100068195
    Abstract: This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.
    Type: Application
    Filed: December 1, 2009
    Publication date: March 18, 2010
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: MICHEL C. VELLARD, VISH KOPPAKA
  • Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
    Patent number: 7560263
    Abstract: The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: July 14, 2009
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Emil D. Kakkis, Michel C. Vellard, Mubarack Muthalif
  • COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE AND METHODS OF TREATING CANCER USING COMPOSITIONS THEREOF
    Publication number: 20090047268
    Abstract: The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.
    Type: Application
    Filed: April 22, 2008
    Publication date: February 19, 2009
    Applicant: BioMarin Pharmaceutical Inc.
    Inventors: Emil D. Kakkis, Michel C. Vellard, Mubarack Muthalif